Sminu Bose, MD

Gynecologic Medical Oncologist at @MSKcancercenter
Focus in uterine #sarcoma
📚 @columbiacancer @HopkinsMedicine
Tweets are my own

[Sana Hatoum, MD @SanaHatoum]

Grateful to have contributed as the fellow chapter author for the Endometrial Carcinoma chapter alongside @SamBoseMD.

[Brian Chernak, MD @BrianChernak]

Today marks 1 year since the passing of my program director (and many others) Dr. #MarkHeaney, who was a world expert in #mastcelldisorders, #MPN, and #AML for 30+ years, completely committed to patients, education, and family. Would love to hear stories from others to honor him!

[LMSpapers @LmSpapers]

Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250) #sarcoma #leiomyosarcoma https://t.co/cqLvUxyXJX

[Sminu Bose, MD @SamBoseMD]

And that’s a wrap on my last
@ASCO as a fellow!

Check out our #CD40agonist study in advanced #sarcoma with an exciting signal in #DDLPS (mPFS 10.9mo vs. 4mo historical)👉 https://t.co/LHzOEg8bNb

Grateful to @ConquerCancerFd and @quadwfoundation for a #MeritAward! #ASCO2023

[Sminu Bose, MD @SamBoseMD]

So proud of @KristineLacuna for being awarded an #ASCO23 Young Investigator Award, receiving a Conquer Cancer Merit Award, and presenting posters for not one but TWO clinical trials sponsored by NCI CTEP. What a rockstar 🤩 #sarcoma

[Nat'l LMS Foundation @NationalLMSF]

Therapeutic advances in leiomyosarcoma
Kristine Lacuna; Sminu Bose, Mathew Ingham, Gary Schwartz
https://t.co/f7Kzup6Ich

[Sminu Bose, MD @SamBoseMD]

Such a unique experience this past week at the @AACR @ASCO #MCCR22 #Vail workshop. Met amazing oncologists from around the world, learned about clinical trial design with the best PDG, and got to rep @columbiacancer with some of my favorite people ☺️

[Julia McGuinness, MD, MS @JMcGuinnessMD]

@columbiacancer at @ASCO @AACR #VailWorkshop #MCCR22 - just missing @DrDawnHershman! Fantastic week of learning with amazing people

[Breelyn Wilky, MD 🎗 @breelynwilkyMD]

This was solid data and discussion- one of the best presentations of the meeting. Congrats to the investigators and Sminu Bose who positively nailed this talk.

[Sminu Bose, MD @SamBoseMD]

@breelynwilkyMD Thank you! 😊

[Jon Trent, MD, PhD @JTrentMDPhD]

Congrats Dr. Sam Bose on identifying lack of Rad51 and WES alterations associated with favorable outcome EFS in patients with uterine #leiomyosarcoma #ASCO22 #Sarcoma

[Herbert Irving Comprehensive Cancer Center @columbiacancer]

Happening now! @SamBoseMD presents at #ASCO22 👏

[Pawel Sobczuk @pawel_sobczuk]

Durable responses (ORR 27%) to temozolomide and olaparib in uLMS
Markers of response?
- WES alterations, HRD score, functional assays?
🔸RAD51 functional assays seems the most promising
@SamBoseMD #sarcoma #lms #asco22

[Herbert Irving Comprehensive Cancer Center @columbiacancer]

Today at #ASCO22, Sminu Bose, MD, (@SamBoseMD) will share updated results from a phase II of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.

More info: https://t.co/QF1bXZBwNk

[Herbert Irving Comprehensive Cancer Center @columbiacancer]

Great to see Dr. Sminu Bose (@SamBoseMD) at today's poster session.

Don't miss her talk during tomorrow's Clinical Science Symposium! #ASCO22

[Pawel Sobczuk @pawel_sobczuk]

Last minute (between packing socks and shirts) selection of #sarcoma abstracts #ASCO22
+rEECur trial
@emilykeungMD @saxotomy @BrotoJavier @SamBoseMD

[Suzie Siegel @SuzieSiegel]

.@SamBoseMD will present a poster on ATX-101 for #leiomyosarcoma & dedif #liposarcoma at #ASCO22. Is this clinical trial recruiting? https://t.co/EJKOJoZTiW #sarcoma

[Herbert Irving Comprehensive Cancer Center @columbiacancer]

Sminu Bose, MD, (@SamBoseMD), Merit Award winner, mentored by Matt Ingham, MD, and Gary Schwartz, MD.

[Sminu Bose, MD @SamBoseMD]

@SuzieSiegel Yes, recruiting!